Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 27;11:732088. doi: 10.3389/fonc.2021.732088

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhang, Bao, Qiu, Tang, Han, Fu, Sun, Ruan, Wu, Chen and Xu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Competing risk nomogram for predicting leukemia recurrence in acute myeloid leukemia (AML) patients with myeloablative conditioning (MAC) regimen in 1, 2, and 3 years after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In the nomogram, the sum of five variable points is located on the axis of total points, and a line is drawn downward to the cumulative incidence of relapse (CIR) axes to determine the probability of 1-, 2-, and 3-year CIR. (B) The diagrams of the concordance index (C-index) after allo-HSCT. (C) The plot of CIR after risk stratification of the nomogram in the training cohort. By using the scoring system from the nomogram, the median cutoff value was adopted to divide the training cohort into two subgroups after ranking by total score (score: from 0 to 9.73 and from 9.73 to 30.58). Gray’s test was used to examine the difference in CIR between groups. MRD, minimal residual disease; ELN, European LeukemiaNet recommendations; DRI, refined Disease Risk Index.